AbbVie (ABBV) Other financing activities (2012 - 2026)
AbbVie (ABBV) posted quarterly Other financing activities of $2.0 million for Q1 2026, down 97.01% year-over-year from $67.0 million in Q1 2025, and down 98.06% quarter-over-quarter from $103.0 million in Q4 2025.
AbbVie (ABBV) Other financing activities (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Other financing activities for 15 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 97.01% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $107.0 million (down 30.52% YoY), while the FY2025 annual figure was $172.0 million, down 19.63% from the prior year.
- Other financing activities slipped to $2.0 million in Q1 2026 per ABBV's latest filing, from $103.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $177.0 million in Q2 2022 and bottomed at -$157.0 million in Q3 2022.
- Historically, Other financing activities has averaged $35.2 million across 5 years, with a median of $21.0 million in 2022.
- On a YoY basis, Other financing activities climbed as much as 504.76% in 2024 and fell as far as 10200.0% in 2024.
- AbbVie's Other financing activities stood at -$11.0 million in 2022, then jumped by 381.82% to $31.0 million in 2023, then soared by 409.68% to $158.0 million in 2024, then sank by 34.81% to $103.0 million in 2025, then sank by 98.06% to $2.0 million in 2026.
- Business Quant data shows ABBV's Other financing activities at $2.0 million in Q1 2026, $103.0 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.00 Mn |
| Jun 30, 2026 | 25.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | 103.00 Mn |
| Dec 31, 2025 | 103.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Sep 30, 2025 | 8.00 Mn |
| Jun 30, 2025 | -6.00 Mn |
| Jun 30, 2025 | -6.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Dec 31, 2024 | 158.00 Mn |
| Dec 31, 2024 | 158.00 Mn |
| Sep 30, 2024 | 32.00 Mn |
| Sep 30, 2024 | 32.00 Mn |
| Jun 30, 2024 | -103.00 Mn |
| Jun 30, 2024 | -103.00 Mn |
| Mar 31, 2024 | 127.00 Mn |
| Mar 31, 2024 | 127.00 Mn |